Patent application number | Description | Published |
20100008981 | METHODS AND SEQUENCES TO SUPPRESS PRIMATE HUNTINGTON GENE EXPRESSION - Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including | 01-14-2010 |
20100263066 | INERT DNA SEQUENCES FOR EFFICIENT VIRAL PACKAGING AND METHODS OF USE - The instant invention provides an inert DNA sequence having a length of between about 0.5 kb and about 5 kb, wherein said isolated inert DNA sequence does not contain an open reading frame and which is suitable for efficient packaging of expression cassettes comprising a nucleic sequence encoding a therapeutic agent into viral vectors, as well as methods of selecting such inert DNA sequences. The invention also provides DNA constructs and medical composition comprising such inert DNA sequences, and kits and medical systems for delivering such DNA constructs and/or compositions. | 10-14-2010 |
20100325746 | Methods and sequences to suppress primate huntington gene expression in vivo - Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including | 12-23-2010 |
20110052666 | Compositions, Methods, and Systems for SIRNA Delivery - The instant invention provides silencer expression cassettes for delivery of RNAi therapy. The silencer cassettes of the instant invention encode an RNAi agent and lack means for replication within a host cell, inverted terminal repeats and further lacking one or more selectable markers. Optionally, the silencer cassettes lack CpG dinucleotides and/or the RNAi agent is within a scaffold of a naturally occurring miRNA. The composition comprising the silencer cassettes of the instant invention, as well as methods of use and suitable systems are also provided. | 03-03-2011 |
20130005794 | METHODS AND SEQUENCES TO SUPPRESS PRIMATE HUNTINGTON GENE EXPRESSION - Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including | 01-03-2013 |
20150126597 | GENISTEIN CANCER TREATMENT REGIMEN MAXIMIZING CANCER RADIATION THERAPY BENEFITS - A treatment regimen for a patient undergoing fractionated radiation therapy for a solid tumor type cancer to attain an improvement in one or more of and an optimized balancing of cancer cell radiation sensitization, normal cell radioprotection, selective post-exposure inhibition of cancer cell recovery relative to normal cell recovery, and stabilization of body weight during radiation treatment. The regimen comprises administration of a therapeutic amount of genistein to a patient diagnosed with a solid tumor type cancer throughout an administration period that commences at least five days prior to commencement of fractionated cancer radiation therapy and extends until at least the conclusion of fractionated cancer radiation therapy. | 05-07-2015 |